

# Alexander M Lila

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5300028/publications.pdf>

Version: 2024-02-01

89  
papers

393  
citations

933264

10  
h-index

940416

16  
g-index

91  
all docs

91  
docs citations

91  
times ranked

177  
citing authors

#	ARTICLE	IF	CITATIONS
1	Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard. <i>Farmakoekonomika</i> , 2021, 13, 388-399.	0.4	43
2	Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 239-254.	0.2	40
3	Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2020, 58, 353-367.	0.2	33
4	“Post-COVID syndrome”: The focus is on musculoskeletal pain. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 255-262.	0.2	17
5	BARICITINIB: NEW PHARMACOTHERAPY OPTIONS FOR RHEUMATOID ARTHRITIS AND OTHER IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2020, 58, 304-316.	0.2	13
6	Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 666-675.	0.2	13
7	Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 367-383.	0.2	12
8	Prospects for the use of chondroitin sulfate and glucosamine sulfate with osteoarthritis associated with pathology of the kidneys and urinary system. <i>Farmakoekonomika</i> , 2020, 13, 23-34.	0.4	11
9	Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2020, 58, 480-488.	0.2	10
10	Is it worthwhile rethinking the positive experience of the last 50 years of using chondroitin sulfates against atherosclerosis?. <i>Farmakoekonomika</i> , 2020, 13, 184-191.	0.4	10
11	Vaccination against SARS-CoV-2 in rheumatic diseases: Safety issues. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2022, 60, 21-31.	0.2	10
12	Standardised Forms of Chondroitin Sulfate as a Pathogenetic Treatment of Osteoarthritis in the Context of Post-Genomic Studies. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 136-143.	0.1	9
13	EFFICACY AND SAFETY OF TOFACITINIB FOR IMMUNEMEDIATED INFLAMMATORY RHEUMATIC DISEASES (PART) <a href="#">Tj ETQq1 1 0,784314</a>	0,2	9
14	The progress of rheumatology in the 21st century potential uses of upadacitinib in rheumatoid arthritis and other inflammatory rheumatic diseases. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2020, 58, 532-543.	0.2	9
15	Hepatoprotective effects of chondroitin sulfate and glucosamine sulfate. <i>Farmakoekonomika</i> , 2022, 14, 537-547.	0.4	8
16	A phase III study of BCD-055 compared with innovator infliximab in patients with active rheumatoid arthritis: 54-week results from the LIRA study. <i>Rheumatology International</i> , 2019, 39, 1537-1546.	1.5	7
17	COVID-19 and rheumatology: A year later. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 31-36.	0.2	7
18	Perspectives of osteoarthritis prevention and therapy personification based on the analysis of comorbid background, genetic polymorphisms and microelement status. <i>Farmakoekonomika</i> , 2021, 14, 28-39.	0.4	7

#	ARTICLE	IF	CITATIONS
19	Osteoarthritis background therapy: current view on the glucosamine and chondroitin therapy. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 112-119.	0.1	7
20	Covid-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab). <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2020, 58, 456-462.	0.2	7
21	Efficacy of netakimab in key psoriatic arthritis domains: 54-week results from the phase III BCD-085-8/PATERA study. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 47-55.	0.2	6
22	Contribution of neurogenic mechanisms to the pathogenesis of chronic joint pain. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 43-49.	0.1	6
23	DO NSAIDS CAUSE SPECIFIC COMPLICATIONS IN COVID-19 CORONAVIRUS INFECTION?. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2020, 58, 340-343.	0.2	6
24	Difficult-to-treat rheumatoid arthritis. What is it?. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 7-11.	0.1	6
25	Early administration of genetically engineered biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An experts' opinion. <i>Al'manah Klinicheskoy Meditsiny</i> , 2020, 48, 422-436.	0.2	6
26	Efficacy of combined use of glycosaminoglycan peptide complex for intramuscular administration and oral diacerein in osteoarthritis: evaluation according to an observational multicenter clinical trial. <i>Terapevticheskii Arkhiv</i> , 2021, 93, .	0.2	5
27	Evaluation of the effectiveness of Tofacitinib in rheumatoid arthritis in real clinical practice: The relationship between pain relief in the first 4 weeks and disease activity after 3-6 months. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 394-400.	0.2	4
28	Safe therapy of osteoarthritis: place of topical nonsteroidal anti-inflammatory drugs. <i>Meditinskiy Sovet</i> , 2020, , 128-134.	0.1	4
29	Osteoarthritis as an interdisciplinary problem: treatment algorithm for physicians and general practitioners. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 68-75.	0.1	4
30	Symptomatic delayed-acting drugs (SYSADOA): new applications. <i>Sovremennaya Revmatologiya</i> , 2022, 16, 99-106.	0.1	4
31	Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 58, 631-636.	0.2	3
32	ANTIPHOSPHOLIPID SYNDROME AND SYSTEMIC LUPUS ERYTHEMATOSUS: WHAT DISEASE IS A CAUSE OF ORGAN DAMAGES?. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2020, 58, 225-231.	0.2	3
33	Medical and social significance and calculation of the economic burden of axial spondyloarthritis in the Russian Federation. <i>Sovremennaya Revmatologiya</i> , 2022, 16, 20-25.	0.1	3
34	Perioperative pharmacotherapy for endoprosthetics: potential of chondroitin sulfate and glucosamine sulfate. <i>Farmakoekonomika</i> , 2022, 15, 162-169.	0.4	3
35	Remote monitoring of patients with axial spondyloarthritis during the COVID-19 pandemic: results and prospects of using the information technology "Aspine". <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 58, 683-690.	0.2	2
36	Dynamics of traditional modifiable risk factors, total cardiovascular risk, and structural changes of carotid arteries in patients with rheumatoid arthritis on long-term interleukin-6 receptor antagonist treatment. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 84-92.	0.2	2

#	ARTICLE	IF	CITATIONS
37	Comprehensive approach to the choice of therapy in patients with osteoarthritis at the first visit to the doctor. Expert consensus (literature review and resolution). <i>Sovremennaya Revmatologiya</i> , 2021, 15, 111-116.	0.1	2
38	Efficacy of Chondroitin Sulfate in Patients with Knee and Hip Osteoarthritis. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 120-125.	0.1	2
39	Satisfaction with analgesic therapy in patients with rheumatic diseases in real clinical practice, according to the KOMPAS study (Quality of Pain Relief in the Opinion of Patients with Arthritis and) <i>Tj ETQq1 1 0.784314 rgBT /Overlock</i>		
40	Extra criterial antiphospholipid antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus (preliminary data). <i>Sovremennaya Revmatologiya</i> , 2021, 15, 18-25.	0.1	2
41	Pharmacoinformation studies of chondroprotectors. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 114-120.	0.1	2
42	Comparison of the effectiveness of subacromial administration of platelet-rich plasma and hyaluronic acid in chronic shoulder pain caused by damage to the tendons of the rotator cuff muscles according to a 6-month open clinical study. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2020, 58, 570-576.	0.2	2
43	Advances in rheumatology at the beginning of the 21st century. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2022, 60, 5-20.	0.2	2
44	Prediction of the development of postoperative pain in patients with late-stage knee osteoarthritis based on the expression of genes for degradation of the extracellular matrix, inflammation and apoptosis in the blood. <i>Sovremennaya Revmatologiya</i> , 2022, 16, 42-49.	0.1	2
45	Psychiatric aspects of spondyloarthritis. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 58, 716-724.	0.2	1
46	Efficiency and safety of magnetotherapy in the treatment of osteoarthritis. Expert council (3 june) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50</i>	0.2	1
47	The 2019 updated EULAR/ERA-EDTA guidelines for the management of lupus nephritis. Expert comments. Part II. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 9-14.	0.1	1
48	Autologous hematopoietic stem cell transplantation in the treatment of systemic sclerosis. Part 2. Safety and complications. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 66-72.	0.1	1
49	Locomotive syndrome: from paradigms to clinical reality. <i>Terapevticheskii Arkhiv</i> , 2021, 93, .	0.2	1
50	Use of tanezumab for chronic pain treatment. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 192-200.	0.2	1
51	Forecasting index of unfavorable outcomes of systemic lupus erythematosus. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 98-102.	0.1	1
52	Assessment of the activity and organ damage in antiphospholipid syndrome. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 101-106.	0.1	1
53	Study of antiphospholipid antibodies by enzyme immunoassay and chemiluminescent methods in patients with antiphospholipid syndrome and systemic lupus erythematosus (preliminary data). <i>Klinicheskaya Laboratornaya Diagnostika</i> , 2021, 66, 546-551.	0.2	1
54	Is there an alternative to diclofenac i/m injections for rapid relief of severe pain? Results of randomized controlled and partially blind forsage study. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2020, 58, 387-394.	0.2	1

#	ARTICLE	IF	CITATIONS
55	Fibromyalgia in rheumatoid arthritis: features of pain syndrome, impact on disease activity and quality of life of patients. <i>Sovremennaya Revmatologiya</i> , 2022, 16, 32-37.	0.1	1
56	Application of chondroprotective agents to inhibit osteodestructive processes in the subchondral bone in patients with osteoarthritis. <i>Farmakoeconomika</i> , 0, , .	0.4	1
57	Effect of colchicine, methotrexate, and hydroxychloroquine therapy on cardiovascular outcomes in patients with calcium pyrophosphate crystal deposition disease. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 76-83.	0.1	1
58	Objective assessment of the damaging effect of glucocorticoids (toxicity index) in patients with systemic lupus erythematosus. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 111-116.	0.1	1
59	Results of an open multicenter non-interventional study of clinical efficacy and tolerability of etoricoxib in osteoarthritis and nonspecific back pain with additional evaluation of the effect of the drug on the "central" manifestations of pain. <i>Sovremennaya Revmatologiya</i> , 2022, 16, 34-42.	0.1	1
60	Analysis of the mechanisms of development of neuroimmunological consequences of COVID-19 and the possibility of their pharmacological correction. <i>Sovremennaya Revmatologiya</i> , 2022, 16, 92-98.	0.1	1
61	Current possibilities of pharmacological correction of neuroimmune joint damage in patients with knee osteoarthritis in long COVID conditions. <i>Sovremennaya Revmatologiya</i> , 2022, 16, 67-74.	0.1	1
62	Pharmacoeconomic rationale for switching patients with rheumatic diseases from original biologic disease-modifying antirheumatic drugs to biosimilars in context of the Russian healthcare system. <i>Sovremennaya Revmatologiya</i> , 2022, 16, 1-17.	0.1	1
63	Multimorbidity in osteoarthritis. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2022, 60, 306-313.	0.2	1
64	Antibodies to domain I <sup>22</sup> -glycoprotein 1 in patients with antiphospholipid syndrome and systemic lupus erythematosus. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2022, 60, 353-359.	0.2	1
65	The role of microbiome in the pathogenesis of immune-mediated inflammatory diseases: controversial issues. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 15-19.	0.1	0
66	Thromboembolic complications in antiphospholipid syndrome and ankylosing spondylitis (two) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 30</i>	0.1	0
67	T- and B-lymphocytes subpopulations in the early and advanced rheumatoid arthritis. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 17-22.	0.1	0
68	Use of magnetotherapy in complex treatment and rehabilitation of patients with osteoarthritis (based) <i>Tj ETQq0 0 0 rgBT /Overlock 10 T</i> 2021, , 31-35.	0.0	0
69	Combination of ankylosing spondylitis with combined autoinflammatory skin lesions (clinical) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10 T</i>	0.1	0
70	Resolution of the Expert Council "The role of type I interferon inhibitor in the treatment of patients with systemic lupus erythematosus". <i>Sovremennaya Revmatologiya</i> , 2021, 15, 126-128.	0.1	0
71	Difficulties in management of patients with systemic lupus erythematosus and antiphospholipid syndrome in combination with melanoma and infiltrative tuberculosis (clinical observations). <i>Sovremennaya Revmatologiya</i> , 2021, 15, 87-93.	0.1	0
72	Molecular basis for new approaches to therapy of osteoarthritis (part I). <i>Sovremennaya Revmatologiya</i> , 2021, 15, 7-12.	0.1	0

#	ARTICLE	IF	CITATIONS
73	The use of biosimilars as a new approach to the treatment of rheumatoid arthritis. Meditsinskiy Sovet, 2021, , 112-121.	0.1	0
74	Insulin resistance and type 2 diabetes mellitus risk factors in systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya, 2021, 59, 406-410.	0.2	0
75	Comparison of standard radiography and magnetic resonance imaging in hand osteoarthritis. Nauchno-Prakticheskaya Revmatologiya, 2021, 59, 418-425.	0.2	0
76	Determination of the accuracy of osteoporotic fractures risk assessment in patients with rheumatoid arthritis using the prognostic model, developed at V.A. Nasonova Research Institute of Rheumatology, and the FRAX algorithm. Sovremennaya Revmatologiya, 2021, 15, 51-56.	0.1	0
77	Netosis in the pathogenesis of antiphospholipid syndrome and systemic lupus erythematosus. Sovremennaya Revmatologiya, 2021, 15, 96-102.	0.1	0
78	Evaluation of the effectiveness of intra-articular administration of highly purified hyaluronic acid in knee osteoarthritis in real clinical practice. Sovremennaya Revmatologiya, 2021, 15, 57-61.	0.1	0
79	Efficacy and safety of two "Carmolis" forms for combined local therapy of knee osteoarthritis: results of a multicenter clinical trial. Klinikist, 2020, 14, 100-106.	0.1	0
80	Intra-articular glucocorticoid injection site: best practice guidelines. Meditsinskiy Sovet, 2021, , 155-162.	0.1	0
81	Dynamics of T- and B-lymphocytes in patients with rheumatoid arthritis, receiving biological disease-modifying antirheumatic drugs. Sovremennaya Revmatologiya, 2022, 16, 38-45.	0.1	0
82	Important aspects of osteoarthritis therapy during the COVID-19 pandemic. Sovremennaya Revmatologiya, 2022, 16, 108-114.	0.1	0
83	Treatment of patients with systemic lupus erythematosus without glucocorticoids " myth or reality?. Sovremennaya Revmatologiya, 2022, 16, 77-83.	0.1	0
84	Analysis of the factors determining the development of postoperative pain in patients after knee and hip replacement surgery. Sovremennaya Revmatologiya, 2021, 15, 19-25.	0.1	0
85	Therapeutic potential of a drug based on avocado and soy unsaponifiable compounds in the treatment of osteoarthritis: data from Russian and international studies (descriptive review). Sovremennaya Revmatologiya, 2022, 16, 48-55.	0.1	0
86	Systematic review and meta-analysis: risk factors for psoriatic arthritis. Part 2. Sovremennaya Revmatologiya, 2022, 16, 26-33.	0.1	0
87	Clinical significance of antibodies to the phosphatidylserine/prothrombin complex. Sovremennaya Revmatologiya, 2022, 16, 81-86.	0.1	0
88	Antibodies to the phosphatidylserine/prothrombin complex in the diagnosis of antiphospholipid syndrome. Terapevticheskiy Arkhiv, 2022, 94, 628-634.	0.2	0
89	Analysis of 5-year clinical and radiological outcomes in patients with psoriatic arthritis observed as part of the Treat to target strategy. Preliminary data. Sovremennaya Revmatologiya, 2022, 16, 14-20.	0.1	0